FDA’s Mermaid Problem: Makena and Pharmaceutical Half-Breeds
This article was originally published in RPM Report
The Makena controversy is moving to court, and likely to a very unhappy ending for KV Pharma. But FDA’s decidedly unusual communications about compounding in the midst of that controversy may have longer term implications.
You may also be interested in...
Wall Street remains hypersensitive to threats from Washington or the campaign trail to take action to limit prescription drug pricing. But it is still hard to see why the threat is any greater because the Clinton campaign has a “plan” to address the issue.
FDA has updated its Orphan Drug regulations, finalizing new language attempting to clarify what subpopulations qualify for the incentive. But it is much easier to say what doesn't cut it than what does.
FDA Commissioner Margaret Hamburg has had some trouble at Congressional hearings, but she has made considerable headaway in her interactions with one key legislator, House Appropriations Committee Chair Rogers.